<DOC>
	<DOCNO>NCT00097435</DOCNO>
	<brief_summary>This Phase 2 , multi-center , randomize , open-label study evaluate safety , tolerability , efficacy Albuferon subject hepatitis C ( HEP C ) fail respond previous interferon alfa therapy .</brief_summary>
	<brief_title>A Study Albuferon With Ribavirin Interferon Treatment Experienced Subjects With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Major Have clinical diagnosis chronic HEP C establish basis detectable viral load , measure serum HCV RNA test screening period . Have previously fail respond treatment interferon alfa ( IFNa ) product Have compensate liver disease follow minimum criterion : white blood cell count &gt; 3,000/mm3 , absolute neutrophil count ( ANC ) &gt; 2,000/mm3 , platelet &gt; 125,000/mm3 , hemoglobin ( Hb ) &gt; 13 g/dL male &gt; 12 g/dL female . Major Evidence decompensated cirrhosis portal hypertension . Pregnant lactate female . History medical disease condition would make subject ( opinion investigator ) unsuitable study . A current drug alcohol addiction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>